Latest news with #ROS
Business Wire
5 days ago
- Business
- Business Wire
Sensus Healthcare Engages Radiology Oncology Systems (ROS) as Primary Distribution Partner for its SRT Systems to Radiation Oncologists
BUSINESS WIRE)-- Sensus Healthcare, Inc. (Nasdaq: SRTS) (Sensus or the Company), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it has entered into a strategic agreement with Radiology Oncology Systems (ROS) to serve as the Company's primary distribution partner for the U.S. radiation oncology market. Under the terms of the agreement, ROS will be responsible for selling Sensus's superficial radiotherapy (SRT) systems, including the SRT-100™ and the SRT-100 Vision™, to hospital-based radiation oncology departments and freestanding oncology centers nationwide. Led by President and CEO John Vano, ROS brings nearly three decades of experience and deep-rooted relationships across radiation oncology, including familiarity with the SRT machines. This new partnership will leverage ROS's extensive presence across all 50 states to accelerate adoption of Sensus's image-guided, non-invasive radiotherapy technologies within the oncology continuum of care. Initial orders under the agreement are expected as early as the fourth quarter of 2025, with the potential to expand the distribution agreement to select international markets in the future. 'The benefits of our SRT systems are increasingly being recognized by largely untapped markets outside our core focus on dermatology, and we're excited to partner with ROS as we deepen our penetration into the hospital-based oncology market,' said Joe Sardano, Chairman and CEO of Sensus Healthcare. 'John and his team have an excellent reputation for delivering value and reliability to radiation oncology departments and clinics. We believe this collaboration will meaningfully accelerate the placement of SRT systems into cancer centers that are seeking non-invasive solutions with excellent aesthetic outcomes and minimal disruption to clinical workflows.' 'Sensus's SRT platform represents an important and growing modality within radiation oncology. By integrating these systems into hospital settings and outpatient oncology centers, we can help providers offer more flexible treatment options while enhancing overall workflow efficiency, patient access and customer satisfaction. We're proud to bring our commercial infrastructure to this partnership and look forward to working closely with the Sensus team to bring SRT to more oncology practices across the country,' commented Mr. Vano. This partnership marks another step in Sensus's strategy to expand beyond dermatology and into hospital and multidisciplinary oncology environments. The Company continues to invest in commercialization and reimbursement initiatives to support broader adoption of its superficial radiation technologies across priority markets. About Sensus Healthcare Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit Forward-Looking Statements This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," 'approximately,' "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release, as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; the performance of the Company's information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Time of India
07-06-2025
- Science
- Time of India
Russia patents drone tech: Orbital station to launch spacecraft automatically; robots to maintain station
Russia patents space technology, uses robots for maintenance of orbital stations (Representative image: PTI) Russia has developed and patented a new technology that allows spacecraft to be launched automatically from an orbital station, Russian news agency TASS reported. This system also includes robotic maintenance features, making it the first of its kind in the world. The technology will be tested at the upcoming Russian Orbital Station (ROS), and later used in future lunar exploration missions . Russia's first deputy Prime Minister Denis Manturov informed President Vladimir Putin about the developments of this technology, emphasising at Russia's need to transition to its own orbital station, module-by-module by 2030. The ROS 'will become the world's first drone platform equipped with robots for its maintenance. This is a patented solution of the Russian Federation,' Manturov said during the meeting on Friday, as reported by PTI. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo The meeting was chaired by Putin through a televised medium to assess the current national projects, particularly in the field of space. Work is currently underway to develop the Russian Orbital Station (ROS), which is planned for deployment in a near-polar orbit between 2027 and 2033. The scientific and power module (SPM), representing the first segment of the ROS, is scheduled for launch at the end of 2027. By 2030, additional components including the universal-node, gateway, and base modules are planned for launch, which together with the SPM will form the station's core infrastructure. The second phase of the station's deployment will involve expanding the facility by docking two target modules between 2031 and 2033. The deployment of Russia's orbital station is expected to begin after the scheduled deorbiting of the International Space Station by 2030. This transition comes after valuable joint space collaboration experience between Roscosmos and Nasa.
Cision Canada
05-06-2025
- Health
- Cision Canada
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
MOMENCE, Ill., June 5, 2025 /CNW/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign's ability to regulate multiple pathways of ROS production. Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity. "These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function," said J. Randal Wexler, FutureCeuticals' General Counsel and Vice President of R&D. "Previously, we've shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time." Wexler added, "These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign's potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support." About FutureCeuticals: FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.
New Indian Express
04-06-2025
- Health
- New Indian Express
IISc Bengaluru develops nanozymes to prevent excess clotting
BENGALURU: A team of researchers from the Indian Institute of Science (IISc), Bengaluru, have developed a new method which will help control abnormal blood clotting conditions, including Pulmonary Thromboembolism (PTE). The team from Department of Inorganic and Physical Chemistry have developed an artificial metal-based nanosyme that mimics the activity of natural antioxidant enzymes which help in clotting blood. The research paper — Vanadia Nanozymes Inhibit Platelet Aggregation, Modulate Signaling Pathways and Prevent Pulmonary Embolism in Mice — published on May 11 was made public on Tuesday. It explained that under normal circumstances, when a blood vessel is injured, specialised blood cells called platelets get activated and cluster together around the vessel to form protective blood clots. This process is known as blood clotting cascade (haemostasis). But when this does not happen in conditions like PTE or diseases like Covid-19, the oxidative stress and levels of toxic Reactive Oxygen Species (ROS) increases, leading to over-activation of platelets. This triggers the formation of excess clots in the blood vessel, contributing to thrombosis, a major cause of morbidity and mortality. The nanomaterials developed by the researchers mimic the activity of natural antioxidant enzymes and they control the ROS levels, thereby preventing the over-activation of platelets that leads to excess clot formation or thrombosis, the report stated. The team synthesised redox active nanomaterials of different sizes, shapes and morphologies through a series of controlled chemical reactions starting from small building blocks. They then isolated platelets from human blood, activated them using physiological agonists, and tested how effectively the different nanozymes could prevent excess platelet aggregation, the researchers explained in the report. Sherin GR, PhD student and co-author of the paper said, they found spherical-shaped vanadium pentoxide nanozymes were the most efficient. These material mimic a natural antioxidant enzyme called glutathione peroxidase to reduce oxidative stress. 'The unique chemistry of the vanadium metal is crucial because the redox reactions that reduce ROS levels are happening on the surface of the vanadium nanomaterial,' added G Mugesh, Professor, and co-author of the paper.
The Hindu
03-06-2025
- Health
- The Hindu
IISc researchers develop novel nanozyme which prevents excess clotting
Researchers at the Indian Institute of Science (IISc.) have developed an artificial metal-based nanozyme that can potentially be used to clamp down on abnormal blood clotting caused by conditions like pulmonary thromboembolism (PTE). According to IISc., under normal circumstances, when a blood vessel is injured, specialised blood cells called platelets get activated, and cluster together around the vessel to form protective blood clots. This process, known as the blood clotting cascade (haemostasis), involves a complex series of protein interactions triggered by signals from physiological agonists (chemicals), such as collagen and thrombin. However, when these signals go haywire in conditions like PTE or diseases like COVID-19, oxidative stress and levels of toxic Reactive Oxygen Species (ROS) increase, leading to over-activation of platelets. This triggers the formation of excess clots in the blood vessel, contributing to thrombosis, a major cause of morbidity and mortality. To tackle this challenge, researchers led by G. Mugesh, professor in the Department of Inorganic and Physical Chemistry, have developed nanomaterials that mimic the activity of natural antioxidant enzymes, which scavenge reactive oxidative molecules. These nanozymes work by controlling ROS levels, thereby preventing the over-activation of platelets that leads to excess clot formation or thrombosis. The team synthesised redox active nanomaterials of different sizes, shapes, and morphologies via a series of controlled chemical reactions starting from small building blocks. They then isolated platelets from human blood, activated them using physiological agonists, and tested how effectively the different nanozymes could prevent excess platelet aggregation. The team found that spherical-shaped vanadium pentoxide (V2O5) nanozymes were the most efficient. These materials mimic a natural antioxidant enzyme called glutathione peroxidase to reduce oxidative stress. 'The unique chemistry of the vanadium metal is crucial because the redox reactions that reduce ROS levels are happening on the surface of the vanadium nanomaterial,' said Prof. Mugesh. The team injected the nanozyme in a mouse model of PTE. They found that it significantly reduced thrombosis and increased the animals' survival rates. They also observed the weight, behaviour, and blood parameters of the animal for up to five days after injecting the nanozyme, and did not find any toxic effects. The team now plans to explore the efficacy of the nanozyme in preventing ischemic stroke, which is also caused by clogging of blood vessels. 'We are hopeful about clinical studies in humans because we have done our experiments with human platelets, and they worked,' said Prof. Mugesh.
